130 studies found for:    "HIV Preventive Vaccine" [CONDITION]
Show Display Options
Download search resultsDownload the search results for:
"HIV Preventive Vaccine" [CONDITION] (130 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Active, not recruiting Safety of and Immune Response to a DNA HIV Vaccine Boosted With a Modified Vaccinia HIV Vaccine and Protein HIV Vaccine in Healthy Adults
Conditions: HIV Seronegativity;   HIV Preventive Vaccine
Interventions: Biological: MVA-C + gp140/MF59;   Biological: DNA-C2 + MVA-C;   Biological: DNA-C2 + MVA-C + gp140/MF59
2 Completed A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.
Condition: HIV Infections
Interventions: Biological: MN rgp120/HIV-1;   Biological: TBC-3B Vaccine
3 Completed A Study to Evaluate the Safety of the HIV-1 Vaccine MVA-B in Chronic HIV-1 Infected Patients Successfully Treated With HAART
Condition: HIV Infection
Interventions: Drug: Vaccination;   Drug: Placebo
4 Active, not recruiting Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine;   Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine;   Biological: DNA vaccine placebo;   Biological: HIV-1 recombinant adenovirus vaccine placebo
5 Completed A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals
Condition: HIV Infections
Interventions: Biological: Aluminum hydroxide;   Biological: Lipid A, Monophosphoryl;   Biological: Lipid A, Liposome-encapsulated monophosphoryl;   Biological: Syntex adjuvant formulation;   Biological: MF59;   Biological: Threonyl Muramyl Dipeptide;   Biological: rgp120/HIV-1 SF-2;   Biological: MTP-PE/MF59
6 Completed Safety and Effectiveness of PENNVAX-B Vaccine Alone, With Il-12, or IL-15 in Healthy Adults
Condition: HIV Infections
Interventions: Biological: PennVax B;   Biological: IL-12;   Biological: IL-15
7 Recruiting Cohort Study of Volunteers That Have Participated to Preventive HIV-1 Vaccine Trials
Conditions: HIV Infection;   HIV Seronegativity
Intervention:
8 Completed Safety of and Immune Response to an HIV Preventive Vaccine (HIV-1 Gag DNA Alone or With IL-15 DNA) Given With or Without 2 Different Booster Vaccinations in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: HIV-1 gag DNA;   Biological: IL-15 DNA adjuvant;   Biological: IL-12 DNA adjuvant
9 Completed Safety of and Immune System Response to an HIV Vaccine (EP HIV-1090) in HIV Uninfected Adults
Condition: HIV Infections
Intervention: Biological: EP HIV-1090
10 Completed Safety of and Immune Response to an HIV-1 Vaccine Boost (VRC-HIVADV014-00-VP) in HIV Uninfected Adults Who Participated in HVTN 052
Condition: HIV Infections
Intervention: Biological: VRC-HIVADV014-00-VP
11 Completed Safety of and Immune Response to a Combination HIV Vaccine Regimen in HIV Uninfected Adults
Condition: HIV Infections
Interventions: Biological: Clade B gag DNA/PLG and env DNA/PLG Microparticles;   Biological: Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant
12 Completed A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 mcg of Env 2-3 in MF59
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: Env 2-3
13 Completed A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: MF59;   Biological: rgp120/HIV-1 SF-2
14 Completed Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B
Condition: HIV Infections
Interventions: Biological: ALVAC(2)120(B,MN)GNP (vCP1452);   Biological: MN rgp120/HIV-1 and GNE8 rgp120/HIV-1
15 Completed Safety of the EnvPro HIV Vaccine in Healthy Volunteers
Condition: HIV Infections
Intervention: Biological: EnvPro
16 Completed A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV (vCP205) and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Interventions: Biological: ALVAC-HIV MN120TMG (vCP205);   Biological: ALVAC-RG Rabies Glycoprotein (vCP65);   Biological: rgp120/HIV-1 SF-2
17 Completed A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults
Condition: HIV Infections
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: rgp120/HIV-1MN
18 Completed Safety and Effectiveness of Administering an HIV Vaccine in the Groin Versus the Arm
Conditions: HIV Infections;   HIV Seronegativity
Intervention: Biological: ALVAC-HIV (vCP205)
19 Completed The Effectiveness of Human Antibodies in Influencing an AIDS-Like Disease in Monkeys
Condition: HIV Infections
Interventions: Biological: gp160 MN/LAI-2;   Biological: Aluminum hydroxide
20 Withdrawn Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Conditions: HIV Infections;   HIV Seronegativity
Interventions: Biological: Aluminum hydroxide;   Biological: QS-21;   Biological: MN rsgp120/HIV-1

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years